tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Lichen Nitidus D017513 1 associated lipids
Lichenoid Eruptions D017512 1 associated lipids
Lymphocele D008210 1 associated lipids
Colitis, Collagenous D046729 1 associated lipids
Malacoplakia D008287 1 associated lipids
Myoclonic Cerebellar Dyssynergia D002527 1 associated lipids
Eye Diseases, Hereditary D015785 1 associated lipids
Feline Infectious Peritonitis D016766 1 associated lipids
Meningitis, Cryptococcal D016919 1 associated lipids
Oculomotor Nerve Diseases D015840 1 associated lipids
Cutis Laxa D003483 1 associated lipids
Invasive Pulmonary Aspergillosis D055744 1 associated lipids
Intestinal Volvulus D045822 1 associated lipids
Hand Injuries D006230 1 associated lipids
Beckwith-Wiedemann Syndrome D001506 1 associated lipids
IgG Deficiency D017099 1 associated lipids
Deltaretrovirus Infections D006800 1 associated lipids
Hepatopulmonary Syndrome D020065 1 associated lipids
Herpes Labialis D006560 1 associated lipids
End Stage Liver Disease D058625 1 associated lipids
Nocturnal Myoclonus Syndrome D020189 1 associated lipids
Uveomeningoencephalitic Syndrome D014607 1 associated lipids
Myelitis D009187 1 associated lipids
Pseudohypoaldosteronism D011546 1 associated lipids
Dendritic Cell Sarcoma, Interdigitating D054739 1 associated lipids
Polymyositis D017285 1 associated lipids
Scorpion Stings D065008 1 associated lipids
Rotavirus Infections D012400 1 associated lipids
Netherton Syndrome D056770 1 associated lipids
Hepatic Veno-Occlusive Disease D006504 1 associated lipids
West Nile Fever D014901 1 associated lipids
Hypoalbuminemia D034141 1 associated lipids
Arm Injuries D001134 1 associated lipids
Intussusception D007443 1 associated lipids
Thrombotic Microangiopathies D057049 1 associated lipids
Autoimmune Diseases of the Nervous System D020274 1 associated lipids
Lupus Erythematosus, Discoid D008179 1 associated lipids
Lymphocytic Choriomeningitis D008216 1 associated lipids
Erythroplasia D004919 1 associated lipids
Budd-Chiari Syndrome D006502 1 associated lipids
AIDS-Associated Nephropathy D016263 1 associated lipids
Oral Ulcer D019226 1 associated lipids
Epidermolysis Bullosa Dystrophica D016108 1 associated lipids
Primary Graft Dysfunction D055031 1 associated lipids
Esophageal Perforation D004939 1 associated lipids
Epididymitis D004823 1 associated lipids
Pruritus Vulvae D011539 1 associated lipids
Central Serous Chorioretinopathy D056833 1 associated lipids
Feline Acquired Immunodeficiency Syndrome D016181 1 associated lipids
Porokeratosis D017499 1 associated lipids
Lentigo D007911 1 associated lipids
Mutism D009155 1 associated lipids
Amyloid Neuropathies D017772 1 associated lipids
Cervical Intraepithelial Neoplasia D018290 1 associated lipids
Migraine with Aura D020325 1 associated lipids
Flaviviridae Infections D018178 1 associated lipids
Idiopathic Interstitial Pneumonias D054988 1 associated lipids
Dysuria D053159 1 associated lipids
Denys-Drash Syndrome D030321 1 associated lipids
Akinetic Mutism D000405 1 associated lipids
Sleep Apnea, Central D020182 1 associated lipids
Orchitis D009920 1 associated lipids
Phyllodes Tumor D003557 1 associated lipids
Meningitis, Fungal D016921 1 associated lipids
Malocclusion, Angle Class II D008312 1 associated lipids
Vulvar Lichen Sclerosus D007724 1 associated lipids
Cardiomyopathy, Restrictive D002313 1 associated lipids
Paraparesis, Tropical Spastic D015493 1 associated lipids
Neurodermatitis D009450 1 associated lipids
Posterior Leukoencephalopathy Syndrome D054038 1 associated lipids
Ecthyma, Contagious D004474 1 associated lipids
Priapism D011317 1 associated lipids
Mediastinal Diseases D008477 1 associated lipids
Hypophosphatemia D017674 1 associated lipids
Leukemia, Myeloid, Chronic-Phase D015466 1 associated lipids
Myelinolysis, Central Pontine D017590 1 associated lipids
Protoporphyria, Erythropoietic D046351 1 associated lipids
Smooth Muscle Tumor D018235 1 associated lipids
Coproporphyria, Hereditary D046349 1 associated lipids
Ichthyosiform Erythroderma, Congenital D016113 1 associated lipids
Panniculitis, Lupus Erythematosus D015435 1 associated lipids
Retrognathia D063173 1 associated lipids
Lacerations D022125 1 associated lipids
Megacolon, Toxic D008532 1 associated lipids
Tinea Capitis D014006 1 associated lipids
Digestive System Fistula D016154 1 associated lipids
Crigler-Najjar Syndrome D003414 1 associated lipids
Leukoplakia, Oral D007972 1 associated lipids
Peroneal Neuropathies D020427 1 associated lipids
Poxviridae Infections D011213 1 associated lipids
Kaposi Varicelliform Eruption D007617 1 associated lipids
Rheumatoid Nodule D012218 1 associated lipids
Hernia, Ventral D006555 1 associated lipids
Hepatitis, Autoimmune D019693 1 associated lipids
Moyamoya Disease D009072 1 associated lipids
Polyomavirus Infections D027601 1 associated lipids
Lymphohistiocytosis, Hemophagocytic D051359 1 associated lipids
Multiple Endocrine Neoplasia Type 2a D018813 1 associated lipids
Apraxias D001072 1 associated lipids
Hypertensive Encephalopathy D020343 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Vohra S et al. Clinical and serological efficacy of topical calcineurin inhibitors in oral lichen planus: a prospective randomized controlled trial. 2016 Int. J. Dermatol. pmid:26147635
Anderson K et al. A retrospective analysis of pediatric patients with lichen sclerosus treated with a standard protocol of class I topical corticosteroid and topical calcineurin inhibitor. 2016 J Dermatolog Treat pmid:26138407
Moes DJ et al. Response: Limited sampling strategies for once daily tacrolimus exposure monitoring. 2016 Eur. J. Clin. Pharmacol. pmid:26931555
Merino D et al. Different in vitro proliferation and cytokine-production inhibition of memory T-cell subsets after calcineurin and mammalian target of rapamycin inhibitors treatment. 2016 Immunology pmid:26931075
Doke T et al. Post-Transplant Membranous Nephropathy Associated with Chronic Active Antibody-Mediated Rejection and Hepatitis C Infection after Deceased Donor Renal Transplantation. 2016 Intern. Med. pmid:26875963
Wen X et al. Comparison of Utilization and Clinical Outcomes for Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients. 2016 Am. J. Transplant. pmid:27137884
Torrisi JS et al. Inhibition of Inflammation and iNOS Improves Lymphatic Function in Obesity. 2016 Sci Rep pmid:26796537
Chatterjee S and Agrawal D Tacrolimus in Corticosteroid-Refractory Vernal Keratoconjunctivitis. 2016 Cornea pmid:27310883
Yan L et al. Donor ABCB1 3435 C>T genetic polymorphisms influence early renal function in kidney transplant recipients treated with tacrolimus. 2016 Pharmacogenomics pmid:26784512
Wu YJ et al. Safe One-to-One Dosage Conversion From Twice-Daily to Once-Daily Tacrolimus in Long-Term Stable Recipients After Liver Transplantation. 2016 Ann. Transplant. pmid:26782179
First MR et al. Use of low-dose tacrolimus and associated hypomagnesemia in the prevention of erectile dysfunction following prostatectomy for prostate cancer. 2016 Pharmacol Rep pmid:27607363
Pereira M et al. Hyperacute Rejection in a Kidney Transplant With Negative Crossmatch: A Case Report. 2016 Transplant. Proc. pmid:27742303
Spain L et al. Management of toxicities of immune checkpoint inhibitors. 2016 Cancer Treat. Rev. pmid:26874776
Ocampo-Garza J et al. Acquired Hyperpigmentation and Cicatricial Alopecia. 2016 Am. J. Med. Sci. pmid:27524226
Jung HJ et al. Improved oral absorption of tacrolimus by a solid dispersion with hypromellose and sodium lauryl sulfate. 2016 Int. J. Biol. Macromol. pmid:26642839
Imai Y et al. Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma. 2016 JCI Insight pmid:27699258
Elshatory YM et al. Diagnostic and Therapeutic Challenges. 2016 Retina (Philadelphia, Pa.) pmid:26225484
Thevissen K How promising are combinatorial drug strategies in combating Candida albicans biofilms? 2016 Future Med Chem pmid:27463947
Li X and Sun S Targeting the fungal calcium-calcineurin signaling network in overcoming drug resistance. 2016 Future Med Chem pmid:27463738
Jung H et al. FK506 regulates pigmentation by maturing the melanosome and facilitating their transfer to keratinocytes. 2016 Pigment Cell Melanoma Res pmid:26581186
Belliere J et al. Pilot conversion trial from mycophenolic acid to everolimus in ABO-incompatible kidney-transplant recipients with BK viruria and/or viremia. 2016 Transpl. Int. pmid:26575959
Hashimoto K et al. Pure red cell aplasia induced by anti-erythropoietin antibodies, well-controlled with tacrolimus. 2016 Int. J. Hematol. pmid:27338269
Grönhagen CM and Tey HL Meralgia paresthetica successfully treated with topical 0.1% tacrolimus: a case report. 2016 Int. J. Dermatol. pmid:26518996
Korobko IV and Lomonosov KM A pilot comparative study of topical latanoprost and tacrolimus in combination with narrow-band ultraviolet B phototherapy and microneedling for the treatment of nonsegmental vitiligo. 2016 Dermatol Ther pmid:27329330
Wu H et al. Developmental Neurotoxic Effects of Percutaneous Drug Delivery: Behavior and Neurochemical Studies in C57BL/6 Mice. 2016 PLoS ONE pmid:27606422
McShane AJ et al. Therapeutic drug monitoring of immunosuppressants by liquid chromatography-mass spectrometry. 2016 Clin. Chim. Acta pmid:26721314
Kostereva NV et al. IGF-1 and Chondroitinase ABC Augment Nerve Regeneration after Vascularized Composite Limb Allotransplantation. 2016 PLoS ONE pmid:27272754
Raja R et al. A prospective study of collapsing focal segmental glomerulosclerosis. 2016 Ren Fail pmid:27266801
Ahmad M et al. Effectiveness of minocycline and FK506 alone and in combination on enhanced behavioral and biochemical recovery from spinal cord injury in rats. 2016 Pharmacol. Biochem. Behav. pmid:27106204
Ramachandran R et al. Cyclical cyclophosphamide and steroids is effective in resistant or relapsing nephrotic syndrome due to M-type phospholipase A2 receptor-related membranous nephropathy after tacrolimus therapy. 2016 Kidney Int. pmid:27181781
Kim JM et al. Conversion of once-daily extended-release tacrolimus is safe in stable liver transplant recipients: A randomized prospective study. 2016 Liver Transpl. pmid:26360125
Bican Demir A et al. Two Cases With Developing Neurologic Complications After Liver Transplant. 2016 Exp Clin Transplant pmid:26643318
Al-Maawali AK et al. Modern Treatments and Stem Cell Therapies for Perianal Crohn's Fistulas. 2016 Can J Gastroenterol Hepatol pmid:28053967
Park OJ et al. A combination of excimer laser treatment and topical tacrolimus is more effective in treating vitiligo than either therapy alone for the initial 6 months, but not thereafter. 2016 Clin. Exp. Dermatol. pmid:26299799
Gomes RM et al. Ten-year kidney transplant survival of cyclosporine- or tacrolimus-treated patients in Brazil. 2016 Expert Rev Clin Pharmacol pmid:27181131
Kanazawa H et al. Chemotherapy-induced B-cell depletion in hepatoblastoma patients undergoing ABO-incompatible living donor liver transplantation. 2016 Pediatr Transplant pmid:27012966
Shipley CA and Spivakovsky S Tacrolimus or clobetasol for treatment of oral lichen planus. 2016 Evid Based Dent pmid:27012570
Ko DH et al. Performance Evaluation of a Restored Dimension TACR Assay: An Automated Platform for Measuring the Whole Blood Tacrolimus Concentration. 2016 Clin. Lab. pmid:27012028
Tron C et al. A high performance liquid chromatography tandem mass spectrometry for the quantification of tacrolimus in human bile in liver transplant recipients. 2016 J Chromatogr A pmid:27837999
Dickerson JA et al. Tacrolimus and sirolimus in capillary dried blood spots allows for remote monitoring. 2015 Pediatr Transplant pmid:25414084
Rivelli RF et al. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant. 2015 Nephrology (Carlton) pmid:25404086
Jahan A et al. Clinical efficacy and pharmacokinetics of tacrolimus in children with steroid-resistant nephrotic syndrome. 2015 Pediatr. Nephrol. pmid:26135137
Marquezan MC et al. Effect of Topical Tacrolimus in the Treatment of Thygeson's Superficial Punctate Keratitis. 2015 Am. J. Ophthalmol. pmid:26133248
Birdwell KA et al. Assessment of arterial stiffness using pulse wave velocity in tacrolimus users the first year post kidney transplantation: a prospective cohort study. 2015 BMC Nephrol pmid:26133166
Cury Martins J et al. Topical tacrolimus for atopic dermatitis. 2015 Cochrane Database Syst Rev pmid:26132597
Izumi Y et al. Two cases of refractory polymyositis accompanied with steroid myopathy. 2015 Mod Rheumatol pmid:24533547
Huang X and Xu B Efficacy and Safety of Tacrolimus versus Pimecrolimus for the Treatment of Atopic Dermatitis in Children: A Network Meta-Analysis. 2015 Dermatology (Basel) pmid:26043855
Milam EC et al. Treatment of Scarring Alopecia in Discoid Variant of Chronic Cutaneous Lupus Erythematosus With Tacrolimus Lotion, 0.3. 2015 JAMA Dermatol pmid:26039539
Argudo A et al. Liver Transplant Patient Carriers of Polymorphism Cyp3a5*1 Donors May Need More Doses of Tacrolimus From the First Month After Transplantation. 2015 Transplant. Proc. pmid:26518936
Xia Z et al. Refractory Dyslipidemia After Liver Transplant: Case Study With Successive Histologic Investigations. 2015 Exp Clin Transplant pmid:25924105
Zheng L et al. Simultaneous determination of cortisol, cortisone, 6β-hydroxycortisol and 6β-hydroxycortisone by HPLC. 2015 J Chromatogr Sci pmid:25628347
Gupta G et al. Safe Conversion From Tacrolimus to Belatacept in High Immunologic Risk Kidney Transplant Recipients With Allograft Dysfunction. 2015 Am. J. Transplant. pmid:25988397
Söderlund C and Rådegran G Safety and efficacy of the switch to generic mycophenolate mofetil and tacrolimus in heart transplant patients. 2015 Clin Transplant pmid:25981927
van Boekel GA et al. Limited sampling strategy for prolonged-release tacrolimus in renal transplant patients by use of the dried blood spot technique. 2015 Eur. J. Clin. Pharmacol. pmid:25980838
de Jonge H et al. The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients. 2015 Pharmacogenomics J. pmid:25287072
Lin YK et al. Using Imiquimod-Induced Psoriasis-Like Skin as a Model to Measure the Skin Penetration of Anti-Psoriatic Drugs. 2015 PLoS ONE pmid:26355594
Andrews LM et al. Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients. 2015 Expert Opin Drug Metab Toxicol pmid:25865963
Murata M Prophylactic and therapeutic treatment of graft-versus-host disease in Japan. 2015 Int. J. Hematol. pmid:25864188
Cuervas-Mons V et al. Impact of tacrolimus and mycophenolate mofetil regimen vs. a conventional therapy with steroids on cardiovascular risk in liver transplant patients. 2015 Clin Transplant pmid:25924549
Hategan A and Bourgeois JA Tacrolimus neurotoxicity and the role of the Renin-Angiotensin system. 2015 J Neuropsychiatry Clin Neurosci pmid:25923858
Li JS et al. Angiopoietin-Like-4, a Potential Target of Tacrolimus, Predicts Earlier Podocyte Injury in Minimal Change Disease. 2015 PLoS ONE pmid:26352670
Lin S et al. Interleukin-2 receptor antagonist therapy leads to increased tacrolimus levels after kidney transplantation. 2015 Ther Drug Monit pmid:25162212
Jiang H et al. An acyltransferase domain of FK506 polyketide synthase recognizing both an acyl carrier protein and coenzyme A as acyl donors to transfer allylmalonyl and ethylmalonyl units. 2015 FEBS J. pmid:25865045
Josephson MA et al. American society of Nephrology Quiz and Questionnaire 2014: transplantation. 2015 Clin J Am Soc Nephrol pmid:25862775
Liu S et al. Comparison of tripterygium wilfordii multiglycosides and tacrolimus in the treatment of idiopathic membranous nephropathy: a prospective cohort study. 2015 BMC Nephrol pmid:26637482
Watanabe K et al. The participation of insulin-like growth factor-binding protein 3 released by astrocytes in the pathology of Alzheimer's disease. 2015 Mol Brain pmid:26637371
Kurita T et al. The efficacy of calcineurin inhibitors for the treatment of interstitial lung disease associated with polymyositis/dermatomyositis. 2015 Lupus pmid:25297551
Birdwell KA et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. 2015 Clin. Pharmacol. Ther. pmid:25801146
Shokati T et al. Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS. 2015 J Vis Exp pmid:26575262
Furie R et al. Lessons Learned From the Clinical Trials of Novel Biologics and Small Molecules in Lupus Nephritis. 2015 Semin. Nephrol. pmid:26573553
Abe Y et al. Successful Management of Lupus Nephritis with High Titers of Myeloperoxidase Anti-Neutrophil Cytoplasmic Antibodies Using Tacrolimus. 2015 Intern. Med. pmid:26568012
William BM and de Lima M Sirolimus plus calcineurin inhibitors and methotrexate: is more necessarily better? 2015 Leuk. Lymphoma pmid:25065702
Gu L et al. A retrospective study to compare the use of tacrolimus and cyclosporine in combination with adriamycin in post-transplant liver cancer patients. 2015 Cell Biochem. Biophys. pmid:25287673
Ambrosioni J et al. Role of rhinovirus load in the upper respiratory tract and severity of symptoms in lung transplant recipients. 2015 J. Clin. Virol. pmid:25728070
Marcus EA et al. Successful term pregnancy in an intestine-pancreas transplant recipient with chronic graft dysfunction and parenteral nutrition dependence: a case report. 2015 Transplant. Proc. pmid:25724255
Youbin Z et al. Tumor Necrosis Factor-α-Induced Protein 8-Like 2 Gene Overexpression Prolongs the Survival of Rat Allogeneic Heart Allografts. 2015 Transplant. Proc. pmid:26518962
Schwarz C et al. Tacrolimus, Mycophenolate Mofetil, and Low-Dose Steroids With or Without Interleukin-2 Receptor Antibody Induction Therapy: A Retrospective Cohort Analysis. 2015 Transplant. Proc. pmid:26518948
Ko MS et al. Tacrolimus therapy causes hepatotoxicity in patients with a history of liver disease. 2015 Int J Clin Pharmacol Ther pmid:25740263
Townamchai N et al. A Simple Novel Technique to Estimate Tacrolimus Dosages During the Early Post Kidney Transplantation Period. 2015 Transplant. Proc. pmid:26518946
Cotton D Celebrating the ACP centennial: from the Annals archive. 2015 Ann. Intern. Med. pmid:25560715
Ramesh M et al. A novel phosphatidic acid-protein-tyrosine phosphatase D2 axis is essential for ERBB2 signaling in mammary epithelial cells. 2015 J. Biol. Chem. pmid:25681440
Pascher A et al. Protein kinase C inhibitor sotrastaurin in de novo liver transplant recipients: a randomized phase II trial. 2015 Am. J. Transplant. pmid:25677074
Tavira B et al. The donor ABCB1 (MDR-1) C3435T polymorphism is a determinant of the graft glomerular filtration rate among tacrolimus treated kidney transplanted patients. 2015 J. Hum. Genet. pmid:25673014
Kikuchi T et al. Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma. 2015 Int. J. Hematol. pmid:26440970
Dai DS et al. Protective Effect of Salvia Przewalskii Extract on Puromycin-Induced Podocyte Injury. 2015 Am. J. Nephrol. pmid:26439819
Ceberio I et al. Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant. 2015 Leuk. Lymphoma pmid:24913499
Aouam K et al. Development of Limited Sampling Strategies for the Estimation of Tacrolimus Area Under the Curve in Adult Kidney Transplant Recipients According to the Posttransplantation Time. 2015 Ther Drug Monit pmid:25627405
Farhangian ME et al. Treatment of Alopecia Areata in the United States: A Retrospective Cross-Sectional Study. 2015 J Drugs Dermatol pmid:26355621
Kawahara T et al. The role of NFATc1 in prostate cancer progression: cyclosporine A and tacrolimus inhibit cell proliferation, migration, and invasion. 2015 Prostate pmid:25631176
Palanisamy AP et al. Induction therapy: clinical and quality of life outcomes in aged renal transplant recipients. 2015 Clin Transplant pmid:25557762
Luger T et al. Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants. 2015 Pediatr Allergy Immunol pmid:25557211
Al-Harbi NO et al. Treatment with aliskiren ameliorates tacrolimus-induced nephrotoxicity in rats. 2015 J Renin Angiotensin Aldosterone Syst pmid:24737642
Lawrence MC et al. NFAT targets signaling molecules to gene promoters in pancreatic β-cells. 2015 Mol. Endocrinol. pmid:25496032
Chakraborty S et al. Prediction of in vivo drug performance using in vitro dissolution coupled with STELLA: a study with selected drug products. 2015 Drug Dev Ind Pharm pmid:25494535
Denardi LB et al. Synergistic effects of tacrolimus and azole antifungal compounds in fluconazole-susceptible and fluconazole-resistant Candida glabrata isolates. 2015 Braz. J. Microbiol. pmid:26221097
Scholz FM et al. Focal metatarsal fistulae syndrome affecting a greyhound dog successfully treated with topical 0.1% tacrolimus ointment. 2015 Vet. Dermatol. pmid:26216245
Koster RA et al. The performance of five different dried blood spot cards for the analysis of six immunosuppressants. 2015 Bioanalysis pmid:26045003
Borda B et al. [Frequency of T-cell mediated rejection in new-onset diabetes after kidney transplantation]. 2015 Orv Hetil pmid:26039918
Albring A et al. Relationship between pharmacokinetics and pharmacodynamics of calcineurin inhibitors in renal transplant patients. 2015 Clin Transplant pmid:25557538
Georgakopoulou EA and Scully C Systemic use of non-biologic agents in orofacial diseases: other immunomodulatory agents. 2015 Oral Dis pmid:24028818